Drug Trial Radar · NCT05397496
Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
61
Actual
Start
Oct 3, 2022
Primary completion
May 31, 2027
Study completion May 31, 2027
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- May 31, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multicenter, phase I study, which primary objective is to characterize the safety and tolerability of PIT565 and to identify maximal tolerated doses (MTDs) and/or recommended doses (RDs), schedule and route of administration in relapsed and/or refractory B-cell Non-Hodgkin lymphoma (R/R B-NHL) and relapsed and/or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).
Conditions
- B-cell Non-Hodgkin Lymphoma (B-NHL)
- B-cell Acute Lymphoblastic Leukemia (B-ALL)
Interventions
PIT565Biological
Intravenous (i.v.) infusion or Subcutaneous (s.c.) injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of Dose Limiting Toxicities (DLTs)Time frame: 28 days or 35 days, depending on the dosing schedule
- Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: 21 months
- Frequency of dose interruptionsTime frame: 21 months
- Frequency of dose reductionsTime frame: 21 months
- Dose intensitiesTime frame: 21 months
Locations
18 sites in 9 countries. Site status is shown where the registry gives one.
University Of Miami
Miami, Florida
University of Chicago Medical Center
Chicago, Illinois
The University of Kansas Clinical Research Ctr
Fairway, Kansas
Memorial Sloan Kettering Cancer Ctr
New York, New York
Oregon Health Sciences University
Portland, Oregon
Novartis Investigative Site
Ghent, Belgium
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Shanghai, China
Novartis Investigative Site
Tianjin, China
Novartis Investigative Site
Créteil, France
Novartis Investigative Site
Marseille, France
Novartis Investigative Site
Tel Aviv, Israel
Novartis Investigative Site
Reggio Emilia, RE, Italy
Novartis Investigative Site
Kashiwa, Chiba, Japan
Novartis Investigative Site
Singapore, Singapore
Novartis Investigative Site
Singapore, Singapore
Novartis Investigative Site
Barcelona, Spain
Novartis Investigative Site
Barcelona, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.